BXCL 504
Alternative Names: BXCL-504Latest Information Update: 02 Feb 2024
At a glance
- Originator BioXcel Therapeutics
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Dementia
Most Recent Events
- 10 Jan 2024 Preclinical trials in Dementia in USA (unspecified route) before January 2024 (BioXcel Therapeutics pipeline, January 2024)